News und Analysen
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
3 Top Stocks Under $5
Tiny stocks don't get a lot of love on Wall Street -- and by tiny I mean companies that have a share price of under $5. According to the Securities and Exchange Commission, any stock that trades....
3 Top Stocks Under $5
Tiny stocks don't get a lot of love on Wall Street -- and by tiny I mean companies that have a share price of under $5. According to the Securities and Exchange Commission, any stock that trades....
3 Most Promising Cancer Drugs in Late-Stage Development
Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful....
3 Most Promising Cancer Drugs in Late-Stage Development
Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful....
3 High-Yield Pharmaceutical Stocks
The pharmaceutical industry is a natural hunting ground for reliable income stocks, since people buy drugs in good times and in bad. But which high-yield dividend stocks are actually worthy of....
3 High-Yield Pharmaceutical Stocks
The pharmaceutical industry is a natural hunting ground for reliable income stocks, since people buy drugs in good times and in bad. But which high-yield dividend stocks are actually worthy of....
CVS Health Hopes Partnerships Will Power Growth
CVS Health Corp (NYSE: CVS) has had a rough go of it during the past year. Over the last twelve months, shares in the pharmaceutical drug store chain and pharmacy benefit manager (PBM) have dipped....
CVS Health Hopes Partnerships Will Power Growth
CVS Health Corp (NYSE: CVS) has had a rough go of it during the past year. Over the last twelve months, shares in the pharmaceutical drug store chain and pharmacy benefit manager (PBM) have dipped....
Here's Why Community Health Systems Surged Today
Shares of Community Health Systems (NYSE: CYH), a major operator of U.S. hospitals, jumped 12.8% on Monday before finishing the session about 8.7% higher. The ASL Strategic Value Fund sent a....
Better Buy: Veeva Systems Inc. vs. Cerner Corporation
Veeva Systems (NYSE: VEEV) and Cerner (NASDAQ: CERN) rank as two of the most successful healthcare technology companies of the past five years. Veeva's customer relationship management (CRM) and....
Better Buy: Veeva Systems Inc. vs. Cerner Corporation
Veeva Systems (NYSE: VEEV) and Cerner (NASDAQ: CERN) rank as two of the most successful healthcare technology companies of the past five years. Veeva's customer relationship management (CRM) and....
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years,....
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years,....
3 Top Small-Cap Stocks to Buy in August
Small-cap stocks, or those with a market cap of between $300 million and $2 billion, often get a bad rap on Wall Street. Smaller companies are typically viewed as having untested business models,....